210 related articles for article (PubMed ID: 16338210)
1. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.
Beyersdorf N; Hanke T; Kerkau T; Hünig T
Autoimmun Rev; 2006 Jan; 5(1):40-5. PubMed ID: 16338210
[TBL] [Abstract][Full Text] [Related]
2. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.
Beyersdorf N; Hanke T; Kerkau T; Hünig T
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv91-5. PubMed ID: 16239397
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.
Beyersdorf N; Gaupp S; Balbach K; Schmidt J; Toyka KV; Lin CH; Hanke T; Hünig T; Kerkau T; Gold R
J Exp Med; 2005 Aug; 202(3):445-55. PubMed ID: 16061730
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prevention of experimental autoimmune myocarditis with CD28 superagonists.
Wang S; Liu J; Wang M; Zhang J; Wang Z
Cardiology; 2010; 115(2):107-13. PubMed ID: 19907173
[TBL] [Abstract][Full Text] [Related]
5. CD28 superagonists: mode of action and therapeutic potential.
Hünig T; Dennehy K
Immunol Lett; 2005 Aug; 100(1):21-8. PubMed ID: 16054703
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis.
Tischner D; Weishaupt A; van den Brandt J; Müller N; Beyersdorf N; Ip CW; Toyka KV; Hünig T; Gold R; Kerkau T; Reichardt HM
Brain; 2006 Oct; 129(Pt 10):2635-47. PubMed ID: 16921176
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
8. Large-scale expansion of rat CD4+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation.
Beyersdorf N; Balbach K; Hünig T; Kerkau T
Immunology; 2006 Dec; 119(4):441-50. PubMed ID: 16903867
[TBL] [Abstract][Full Text] [Related]
9. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection.
Kitazawa Y; Fujino M; Sakai T; Azuma H; Kimura H; Isaka Y; Takahara S; Hünig T; Abe R; Li XK
J Heart Lung Transplant; 2008 Apr; 27(4):362-71. PubMed ID: 18374871
[TBL] [Abstract][Full Text] [Related]
10. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A; Beissert S; Krammer PH
Arch Dermatol Res; 2009 Jan; 301(1):71-81. PubMed ID: 18985367
[TBL] [Abstract][Full Text] [Related]
11. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies.
Hünig T
Adv Immunol; 2007; 95():111-48. PubMed ID: 17869612
[TBL] [Abstract][Full Text] [Related]
12. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
Xia G; He J; Zhang Z; Leventhal JR
Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody.
Rodríguez-Palmero M; Franch A; Castell M; Pelegrí C; Pérez-Cano FJ; Kleinschnitz C; Stoll G; Hünig T; Castellote C
J Rheumatol; 2006 Jan; 33(1):110-8. PubMed ID: 16395758
[TBL] [Abstract][Full Text] [Related]
14. Role of regulatory T-cells in autoimmunity.
Mellanby RJ; Thomas DC; Lamb J
Clin Sci (Lond); 2009 Apr; 116(8):639-49. PubMed ID: 19275768
[TBL] [Abstract][Full Text] [Related]
15. Differential changes in CD4+ and CD8+ effector and regulatory T lymphocyte subsets in the testis of rats undergoing autoimmune orchitis.
Jacobo P; Guazzone VA; Jarazo-Dietrich S; Theas MS; Lustig L
J Reprod Immunol; 2009 Jul; 81(1):44-54. PubMed ID: 19520436
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
Ahn JS; Krishnadas DK; Agrawal B
Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
[TBL] [Abstract][Full Text] [Related]
17. In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance.
Jiang S; Golshayan D; Tsang J; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1879-82. PubMed ID: 17161340
[TBL] [Abstract][Full Text] [Related]
18. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382
[TBL] [Abstract][Full Text] [Related]
19. CD28 superagonists: what makes the difference in humans?
Schraven B; Kalinke U
Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
[TBL] [Abstract][Full Text] [Related]
20. The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age.
Simone R; Zicca A; Saverino D
J Leukoc Biol; 2008 Dec; 84(6):1454-61. PubMed ID: 18780874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
